Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q3 FY22 results · Oct–Dec 2021
Panacea Biotec reported revenue from operations of ₹155.88 crore (up 10.0% from Q3 FY21) and net loss of ₹49.20 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 155.88 | 141.76 | +10.0% | 232.17 | −32.9% |
| Other income | 1.66 | 1.89 | −12.2% | 2.03 | −18.2% |
| Total income | 157.54 | 143.65 | +9.7% | 234.20 | −32.7% |
| Profit before tax | (49.16) | (39.96) | Loss widened | (53.01) | Loss narrowed |
| Net profit for the period | (49.20) | (40.05) | Loss widened | (53.01) | Loss narrowed |
| EPS, basic (₹) | (8.03) | (6.54) | Loss widened | (8.65) | Loss narrowed |
| Net margin (%) | -31.6 | -28.3 | -22.8 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 38.48 | 69.02 | −44.2% | 119.26 | −67.7% |
| Other income | 2.38 | 7.17 | −66.8% | 3.47 | −31.4% |
| Total income | 40.86 | 76.19 | −46.4% | 122.73 | −66.7% |
| Profit before tax | (22.43) | 1.91 | Turned loss | (22.37) | Loss widened |
| Net profit for the period | (22.43) | 1.90 | Turned loss | (22.37) | Loss widened |
| EPS, basic (₹) | (3.66) | 0.31 | Turned loss | (3.65) | Loss widened |
| Net margin (%) | -58.3 | 2.8 | -18.8 |
Consolidated
- Filed with BSE
- 17 Feb 2022, 10:24 IST
- Board meeting
- 14 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Feb 2022, 10:24 IST
- Board meeting
- 14 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE